Management Team and Advisors
Francine Foss, MD, Scientific Advisory Board.
Dr. Foss a Professor of Medicine and Co-director of the Hematologic Malignancies Program at the Yale Cancer Center. Dr. Foss is an internationally recognized expert on CTCL and PTCL. Having trained at the Brigham & Women's Hospital and the National Cancer Institute, she established a large program on cutaneous T-cell lymphoma and peripheral T-cell lymphoma at Yale where she has set up numerous population-based and registry studies in T-cell lymphoma and has conducted seminal clinical trials to establish novel therapeutic strategies for T-cell lymphomas. Since 2015 she has served as the Director of the Lymphoma Research Group at the Yale Comprehensive Cancer Center.
William Bishai, MD PhD, co-Founder, Chairman.
Dr. Bishai is co-founder and co-director of the Johns Hopkins Center for TB Research. From early in his career, Dr. Bishai has been an expert in recombinant fusion toxin proteins, the topic of his 1989 PhD research in Dr. Murphy’s lab. Recently, with Dr. Murphy and other colleagues, he was an inventor of SON-211 and related technologies. Dr. Bishai also served as the founding director of the KwaZulu Natal Research Institute for TB and HIV (K-RITH) from 2010 to 2013 - an institute set up in a historic collaboration between the Howard Hughes Medical Institute (HHMI) and the University of KwaZulu Natal (UKZN) in Durban South Africa.
John (Jack) Murphy, PhD, co-Founder, CSO.
Dr. Murphy’s career includes his pioneering work in the fusion protein toxin field at Harvard and then Boston University, which led to the FDA’s approval of Ontak (denileukin diftotox) the first in class targeted therapy for refractory CTCL. Dr. Murphy was a founding scientist in Seragen Inc., where he served on the Board of Directors and Scientific Advisory Board. He has also held several senior academic positions including Lawrence J. Henderson Associate Professor of Health Sciences, Technology and Management at Harvard Medical School, Professor of Medicine and Microbiology and Chief, Section of Molecular Medicine in the Department of Medicine at Boston University and Director of the National Emerging Infectious Diseases Laboratories Institute at Boston University.
Drew Pardoll, MD, PhD, Scientific Advisory Board.
Dr. Pardoll is the Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University, School of Medicine. He is the Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Pardoll has made a number of major discoveries in cellular immunology, including the discovery of one of the two ligands for the PD-1 inhibitory receptor. He leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types. Dr. Pardoll is a founder of Amplimmune and Jounce.